Methylphenidate-induced alterations in synaptic vesicle trafficking and activity: Functional consequences and therapeutic implications

Annals of the New York Academy of Sciences

Volumn 1139, Issue , 2008, Pages 285-290

  Volz, Trent J ^a   Farnsworth, Sarah J ^a   Hanson, Glen R ^a   Fleckenstein, Annette E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Dopamine; Methamphetamine; Methylphenidate; Neurotoxicity; Parkinson's disease; Vesicular monoamine transporter 2

Indexed keywords

DOPAMINE; METHYLPHENIDATE; POTASSIUM; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ATTENTION DEFICIT DISORDER; CONFERENCE PAPER; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG PROTEIN BINDING; EXOCYTOSIS; MALE; NERVE ENDING; NONHUMAN; PARKINSON DISEASE; PROTEIN LOCALIZATION; RAT; SYNAPSE VESICLE; SYNAPTOSOME;

RATTUS;

EID: 53549124425     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1432.012     Document Type: Conference Paper

References (26)

1. Wayment, H.K., H. Deutsch, M.M. Schweri & J.O. Schenk. 1999. Effects of methylphenidate analogues on phenethylamine substrates for the striatal dopamine transporter: potential as amphetamine antagonists? J. Neurochem. 72 : 1266 1274.
2. Volz, T.J. & J.O. Schenk. 2005. A comprehensive atlas of the topography of functional groups of the dopamine transporter. Synapse 58 : 72 94.
3. Volz, T.J., N.L. Bjorklund & J.O. Schenk. 2005. Methylphenidate analogs with behavioral differences interact differently with arginine residues on the dopamine transporter in rat striatum. Synapse 57 : 175 178.
4. Sandoval, V., E.L. Riddle, G.R. Hanson & A.E. Fleckenstein. 2002. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J. Neurosci. 22 : 8705 8710.
5. Truong, J.G., A.H. Newman, G.R. Hanson & A.E. Fleckenstein. 2004. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein. Eur. J. Pharmacol. 504 : 27 32.
6. Volz, T.J., S.J. Farnsworth, J.L. King, et al. 2007. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles. J. Pharmacol. Exp. Ther. 323 : 738 745.
7. Riddle, E.L., M.K. Topham, J.W. Haycock, et al. 2002. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur. J. Pharmacol. 449 : 71 74.
8. Schenk, J.O., C. Wright & N. Bjorklund. 2005. Unraveling neuronal dopamine transporter mechanisms with rotating disk electrode voltammetry. J. Neurosci. Methods. 143 : 41 47.
9. Volz, T.J., G.R. Hanson & A.E. Fleckenstein. 2006. Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry. J. Neurosci. Methods 155 : 109 115.
10. Volz, T.J., G.R. Hanson & A.E. Fleckenstein. 2006. Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function. Synapse 60 : 474 477.
11. Sandoval, V., E.L. Riddle, G.R. Hanson & A.E. Fleckenstein. 2003. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J. Pharmacol. Exp. Ther. 304 : 1181 1187.
12. Truong, J.G., D.G. Wilkins, J. Baudys, et al. 2005. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. J. Pharmacol. Exp. Ther. 314 : 1087 1092.
13. McElvain, J.S. & J.O. Schenk. 1992. Blockade of dopamine autoreceptors by haloperidol and the apparent dynamics of potassium-stimulated endogenous release of dopamine from and reuptake into striatal suspensions in the rat. Neuropharmacology 31 : 649 659.
14. Cubells, J.F., S. Rayport, G. Rajendran & D. Sulzer. 1994. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14 : 2260 2271.
15. Cadet, J.L. & C. Brannock. 1998. Free radicals and the pathobiology of brain dopamine systems. Neurochem. Int. 32 : 117 131.
16. Fumagalli, F., R.R. Gainetdinov, Y.M. Wang, et al. 1999. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19 : 2424 2431.
17. Hanson, G.R., K.S. Rau & A.E. Fleckenstein. 2004. The methamphetamine experience: a NIDA partnership. Neuropharmacology 47 : 92 100.
18. Volz, T.J., G.R. Hanson & A.E. Fleckenstein. 2007. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. J. Neurochem. 101 : 883 888.
19. Volz, T.J., A.E. Fleckenstein & G.R. Hanson. 2007. Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment. Addiction 102 : 44 48.
20. Volkow, N.D., L. Chang, G.J. Wang, et al. 2001. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry. 158 : 377 382.
21. Jenner, P. 1998. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13 : 24 34.
22. Devos, D., P. Krystkowiak, F. Clement, et al. 2007. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 78 : 470 475.
23. Auriel, E., J.M. Hausdorff, T. Herman, et al. 2006. Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study. Clin. Neuropharmacol. 29 : 15 17.
24. Camicioli, R., E. Lea, J.G. Nutt, et al. 2001. Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study. Clin. Neuropharmacol. 24 : 208 213.
25. Chatterjee, A. & S. Fahn. 2002. Methylphenidate treats apathy in Parkinson's disease. J. Neuropsychiatry. Clin. Neurosci. 14 : 461 462.
26. Liu, G. 2003. Presynaptic control of quantal size: kinetic mechanisms and implications for synaptic transmission and plasticity. Curr. Opin. Neurobiol. 13 : 324 331.